Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Article Abstract:
The monoclonal antibody trastuzumab appears to increase the effectiveness of chemotherapy in women with breast cancer that produces excess HER2. HER2 is a growth factor receptor that can shorten survival when present in large amounts.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
From the molecule to the clinic -- inhibiting HER2 to treat breast cancer
Article Abstract:
The development of a monoclonal antibody against epidermal growth factor receptor is a result of research on the molecular biology of breast cancer. When this receptor is present in larger than normal amounts, it causes a more aggressive form of the tumor. It seems to work best when given with chemotherapy.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Article Abstract:
The efficacy of trastuzumab, a recombinant monoclonal antibody against herceptin (HER2), along with its safety after excision of early-stage breast-cancer and completion of chemotherapy is investigated. One year of treatment with trastuzumab after chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Breast cancer. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer
- Abstracts: Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic inflammatory process. A dual function for CD40 agonists
- Abstracts: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism
- Abstracts: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
- Abstracts: A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia